

In re application of:

Carcagno et al.

Appl. No.: 09/830,968

§ 371 Date: November 6, 2001

For: Method for the Massive Culture

of Cells Producing Recombinant

Human Erythropoietin

Confirmation No.: 7301

Art Unit: 1636

Examiner: Kaushal, Sumesh

Atty. Docket: 1909.0040002/JAG/PAJ

First Supplemental Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is provided.

The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed November 6, 2001, in connection with the above-captioned application.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following, in regard to non-English language documents AM2, AN2 and A02 cited on Form PTO-1449:

Document AM2, European Patent Publication No. EP 0 513 738, is in the German language. An unverified English language abstract of document AM2 is attached as document AS20.

Document AN2, PCT Patent Publication No. WO 96/35718, is in the German language.

An English language abstract appears on the face page of said document.

Document AO2, Chinese Patent Publication No. CN 1190130, is in the Chinese language. An unverified English language abstract of document AO2 is attached as document AR20.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Peter A. Jackman

Attorney for Applicants Registration No. 45,986

Date: 21,005 1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600 385043 1.DOC

Page 1 of 2 ATTY, DOCKET NO. APPLICATION NO. 1909.0040002/JAG/PAJ 09/830,968 FORM PTO-1449 APPLICANTS Carcagno et al. FIRST SUPPLEMENT § 371 DATE ART UNIT INFORMATION DISCLOSURE S November 6, 2001 1636 **U.S. PATENT DOCUMENTS EXAMINER** DATE CLASS SUB-CLASS DOCUMENT NUMBER FILING DATE INITIAL NAME AΑ AΒ AC AD ΑE ΑF AG AΗ ΑI ΑJ ΑK FOREIGN PATENT DOCUMENTS **EXAMINER** INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes ΑL No Yes EP 0 513 738 11/19/1992 AM2 Europe X No Yes **WIPO** AN₂ WO 96/35718 11/14/1996 X No Yes CN 1190130 08/12/1998 AO2 China X No Yes AP No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Lee, G.M., et al., "Development of a serum-free medium for the production of erythropoietin AS <u> 19</u> by suspension culture of recombinant Chinese hamster ovary cells using a statistical design," J. Biotechnol. 69:85-93, Elsevier (April 1999) Supplementary European Search Report for European Patent Application No. EP 99 95 8810, AT 19 mailed March 16, 2005, European Patent Office, Rijswijk, Netherlands

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DATE CONSIDERED

EXAMINER

FIRST SUPPLEMENT FORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1909.0040002/JAG/PAJ APPLICATION NO. 09/830,968

Page 2 of 2

APPLICANTS

Carcagno et al.

§ 371 DATE November 6, 2001 ART UNIT 1636

U.S. PATENT DOCUMENTS

				C.D. 1111	ENI DOCUMENTS		·	,
EXAMINER INITIAL		DC	CUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
-	AB							
	AC		- 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.					
<u> </u>	AD		100000000000000000000000000000000000000					
	AE							
10.00	AF		NAME OF THE PARTY					
	AG							
	АН		1					
	AI							
	AJ							
	AK							
		-	F	OREIGN P	ATENT DOCUMENTS			
EXAMINER INITIAL		DC	CUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL							Ye No
	AM							Ye
	AN							Ye.
	AO							Ye
					****			No Ye
	AP							No.
		·····	OTHER (Incl	uding Auth	or, Title, Date, Pertinent	Pages, etc.)		
	AR	20	Derwent World Patents Index, English language abstract for Chinese Patent No. CN 1190130, Accession No. 2003-175924					
	AS	20	Derwent World Patents Index, Dialog File 351, English language abstract for European Patent No. EP 0 513 738, Accession No. 9256229					
	AT							
EXAMINER		L				DATE CO	NSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to Applicant.